Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 202.50

-2.7%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (20879)	5/15/1998 4:34:00 PM
From: Andreas Helke	Read Replies (1) of 32384

Here is an excerpt from thestreet.com coverage of the upcoming ASCO meeting. What I found particularly interesting is that this is an example of an cancer drug where the majority of sales are off label. Andreas Sequus has a bunch of abstracts of studies here at the conference. The company's anticancer drug, Doxil, has been showing steady sales growth, despite that the drug is only approved for Kaposi's sarcoma. The majority of sales is in other cancers. Doxil is a special formulation of a common anticancer compound encased in a fat that is supposed to make it safer and, potentially, more effective. Data on Doxil in refractory ovarian cancer looks promising, but its use in breast cancer, a much larger market, "remains uncertain," according to OpCo. from thestreet.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next